Nutra Pharma (NPHC) Form 4 NUTRA PHARMA / RIK J DEITSCH ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

DEITSCH RIK J

(Last) (First) (Middle)

12538 W. ATLANTIC BLVD.

(Street)

CORAL SPRINGS FL 33071

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NUTRA PHARMA CORP [ NPHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
President, CEO

3. Date of Earliest Transaction (Month/Day/Year)
04/10/2014

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Nutra Pharma Corp Common Stock	04/10/2014		P		1,250,000	A	$0.08	4,791,959	D
Nutra Pharma Corp Common Stock	12/11/2014		A		506,900	A	$0.24	5,298,859	D
Nutra Pharma Corp Common Stock	06/13/2015		A		4,000,000	A	$0.185	9,298,859	D
Nutra Pharma Corp Common Stock	06/28/2016		A		4,000,000	A	$0.0135	13,298,859	D
Nutra Pharma Corp Common Stock	07/05/2016		P		15,000,000	A	$0.0067	28,298,859	D
Nutra Pharma Corp Common Stock	12/19/2016		P		15,000,000	A	$0.005	43,298,859	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Nutra Pharma Series A Preferred	(1)	10/30/2017	(1)	A		3,000,000		(1)	(1)	Series A Preferred	3,000,000	$0.133	3,000,000	D

Explanation of Responses:

1. Preferred shares have no right of conversion and are valued at $0.133 per share, which represents the actual cost paid. The Series A Preferred Stock will vote with the Corporation's common stock as a single class on all matters or consents for the Corporation's common stockholders. Each share of Series A Preferred Stock is entitled to one thousand votes per share.

	/s/ Rik J. Deitsch	06/26/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.